Targeting TTR amyloidosis at its source. Transthyretin (TTR) amyloidosis is a family of rare, devastating diseases with serious unmet medical needs.
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $64M
Founded date: 2013
Investors 5
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | Hercules C... | htgc.com |
| - | RA Capital... | racap.com |
| - | MBC BioLab... | mbcbiolabs... |
| - | Perceptive... | perceptive... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 05.04.2018 | Series B | $64M | - |
Mentions in press and media 5
| Date | Title | Description |
| 15.10.2019 | BridgeBio terminates effort to acquire remainder of Eidos Therapeutics | Eidos trades publicly on the Nasdaq, and its shares fell 6.5 percent Monday morning following the news, remaining down 3.1 percent Tuesday afternoon. BridgeBio’s shares were up 2 percent. The subsidiary, which is headquartered in San Franci... |
| 23.01.2019 | BridgeBio Pharma raises $299.2M in financing round | The company plans to use the money support and expand upon existing research and development programs in genetic diseases. BridgeBio’s practice is to find product candidates, sourced from various academic and research institutions and compa... |
| 05.04.2018 | Eidos Therapeutics Closes $64M Series B Financing | Eidos Therapeutics, Inc., a San Francisco, CA-based clinical stage biopharmaceutical company developing a novel oral therapy to treat transthyretin (TTR) amyloidosis (ATTR), raised $64.0m Series B financing. The round, which brings the tota... |
| - | BridgeBio terminates effort to acquire remainder of Eidos Therapeutics | A firm that helps launch biomedical research into new companies has called off a bid to acquire one of its subsidiaries. Palo Alto, California-based BridgeBio Pharma said Monday that it had terminated a merger process with subsidiary Eidos ... |
| - | BridgeBio Pharma raises $299.2M in financing round | A company focused on developing genetically targeted drugs discovered by academia and then building subsidiary companies around them has raised nearly $300 million in a financing round. Palo Alto, California-based BridgeBio Pharma said Wedn... |